Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Described as likely moderately addictive with a high potential for abuse, capable of causing psychological dependence in some users. Compulsive redosing is commonly reported, particularly during or immediately following the peak effects. Cravings may develop with chronic use.
Withdrawal effects may occur if use is suddenly stopped after dependence has developed, though available reports emphasize psychological rather than physical dependence mechanisms.
The exact toxic dosage is unknown. This is because 3-FEA has an extremely brief history of human use, first becoming available in mid-2016, and its toxicity has not been studied in any scientific context.
Due to its serotonin-releasing entactogenic properties, 3-FEA may display significant activity at the 5-HT2B receptor, which could make it cardiotoxic with long-term or heavy use, similar to MDMA and fenfluramine; acute cardiovascular strain during intoxication has also been reported.
As an amphetamine derivative, abuse at high dosages for prolonged periods can potentially result in stimulant psychosis presenting with paranoia, hallucinations, or delusions. Based on reviews of amphetamine-induced psychosis, approximately 5-15% of affected users fail to recover completely, though antipsychotics effectively resolve acute symptoms. Psychosis very rarely arises from cautious, sparing use at moderate doses.
3-Fluoroethamphetamine belongs to a series of designer fluorinated amphetamine derivatives that emerged in the 2010s, which includes related compounds such as 2-FA, 2-FMA, 3-FA, 4-FMA, and 4-FA. These substances were developed as novel psychoactive compounds for the research chemical market.…
Production and sale prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). This legislation covers novel psychoactive substances not explicitly listed in traditional drug schedules.
As of December 2024, not explicitly listed as a controlled substance. Possession exists in a legal grey area, though this status may change.
Controlled as an amphetamine analog under national drug legislation. Schedule 3 substances are considered to have moderate potential for harm.
Controlled under the amphetamine analog clause of the Misuse of Drugs Act 1971. Class A classification carries the most severe penalties, including up to 7 years for possession and life imprisonment for supply.
Controlled as an amphetamine analog under the Controlled Drugs and Substances Act. Schedule I substances carry the most severe penalties for trafficking and possession.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz since November 26, 2016. Production, import with intent to distribute, administration to others, and commercial trading are criminal offenses. Possession is prohibited but does not carry criminal penalties.
Regulated as a derivative of α-methylphenethylamine under Verzeichnis E point 130 of the narcotics scheduling ordinance. An exemption exists for scientific or industrial applications.
Not explicitly scheduled federally but may be prosecuted under the Federal Analogue Act (21 U.S.C. § 813) as substantially similar to amphetamine. This applies only when the substance is intended for human consumption, potentially subjecting it to Schedule II restrictions.
13 sources cited